“Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s616. doi:10.25251/n1p8w126.